Vestor Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Vestor Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,655	Closed	-$9.01M	–	303
2026 Q1	$9.01M	Buy	11,655 +9,654	+482%	+$7.39M	0.65%	47
2025 Q4	$9.01M	Buy	+2,001	New	+$1.36M	0.62%	36
2023 Q3	–	Sell	-99	Closed	-$71K	–	275
2023 Q2	$71K	Buy	+99	New	+$76.3K	0.01%	205

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Vestor Capital's REGN Position: Q2 2026 in Review

Vestor Capital sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 11,655 shares — an estimated $9.01M sold.

Vestor Capital first reported a position in REGN in Q2 2023 and held it in 3 quarters. The position peaked at $9.01M in Q4 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Vestor Capital reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Vestor Capital sold 11,655 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $9.01M.
Vestor Capital first reported a position in Regeneron Pharmaceuticals in Q2 2023 and held it in 3 quarters.
Vestor Capital's Regeneron Pharmaceuticals position peaked at $9.01M in Q4 2025.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Vestor Capital's 13F filing for Q2 2026, filed 28 Jul 2026.